Business Description
Perspective Therapeutics Inc
NAICS : 339112
SIC : 5047
ISIN : US46489V1044
Total Employee Number:
166Description
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 64.03 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -56.4 | |||||
3-Year EPS without NRI Growth Rate | -42 | |||||
3-Year FCF Growth Rate | -53.9 | |||||
3-Year Book Growth Rate | -4.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 6.61 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.66 | |||||
9-Day RSI | 37.17 | |||||
14-Day RSI | 40.14 | |||||
3-1 Month Momentum % | -30.7 | |||||
6-1 Month Momentum % | 19.71 | |||||
12-1 Month Momentum % | -27.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.75 | |||||
Quick Ratio | 8.75 | |||||
Cash Ratio | 8.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -70.8 | |||||
Shareholder Yield % | -48 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -41.25 | |||||
ROA % | -34.46 | |||||
ROIC % | -95.37 | |||||
3-Year ROIIC % | -54.76 | |||||
ROC (Joel Greenblatt) % | -152.91 | |||||
ROCE % | -37.21 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.98 | |||||
Price-to-Tangible-Book | 1.11 | |||||
EV-to-EBIT | -0.66 | |||||
EV-to-Forward-EBIT | 28.77 | |||||
EV-to-EBITDA | -0.69 | |||||
EV-to-Forward-Revenue | 189.06 | |||||
EV-to-FCF | -0.69 | |||||
| Price-to-Net-Current-Asset-Value | 1.61 | |||||
| Price-to-Net-Cash | 1.64 | |||||
Earnings Yield (Greenblatt) % | -151.52 | |||||
FCF Yield % | -31.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Perspective Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.201 | ||
| Beta | 2.426 | ||
| 3-Year Sharpe Ratio | 0.28 | ||
| 3-Year Sortino Ratio | 0.49 | ||
| Volatility % | 71.29 | ||
| 14-Day RSI | 40.14 | ||
| 14-Day ATR (€) | 0.129764 | ||
| 20-Day SMA (€) | 2.752 | ||
| 12-1 Month Momentum % | -27.75 | ||
| 52-Week Range (€) | 1.66 - 4.92 | ||
| Shares Outstanding (Mil) | 114.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Perspective Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Perspective Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 115 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 26 days | ||
| General meeting for 2026 | 2026-05-27 09:00 | 3.56 (+6.46%) | ||
| Guidance call for 2026 | 2026-05-19 14:05 | 3.18 (+0.00%) | ||
| BofA Securities Health Care Conference | 2026-05-13 17:20 | 3.20 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 2.98 (+0.00%) | ||
| Analyst Event on Perspective\'s Strategy, Enabling Technology, and Pipeline | 2026-05-04 08:30 | 3.25 (+0.00%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-14 09:30 | 3.70 (+0.00%) | ||
| Annual report for 2025 | 2026-03-16 | 4.34 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-16 | 4.34 (+0.00%) |
Show
Entries
Perspective Therapeutics Inc Frequently Asked Questions
What is Perspective Therapeutics Inc(FRA:AAJ0)'s stock price today?
The current price of FRA:AAJ0 is €2.46. The 52 week high of FRA:AAJ0 is €4.92 and 52 week low is €1.66.
When is next earnings date of Perspective Therapeutics Inc(FRA:AAJ0)?
The next earnings date of Perspective Therapeutics Inc(FRA:AAJ0) is 2026-08-13 Est..
Does Perspective Therapeutics Inc(FRA:AAJ0) pay dividends? If so, how much?
Perspective Therapeutics Inc(FRA:AAJ0) does not pay dividend.
Press Release
Articles on Perspective Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers